Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irritation and Sensitization Study of Rotigotine Transdermal System in Healthy Volunteers
NCT02727205Phase 1Completed
- Sponsor
- Inflamax Research
- Start
- Aug 2013
- Primary completion
- Oct 2013
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, single-blind trial of rotigotine in Parkinson's disease (PD), sponsored by Inflamax Research. Primary endpoints: Irritation Potential at 21 days and Sensitization Potential. Started Aug 2013; status: completed.
02
Drugs
rotigotine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02727205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02727205.